Bejescin® (MIL62, Obinutuzumab beta Injection) is a novel 3rd-generation anti-CD20 monoclonal antibody with a unique competitive position in the market, and has been approved by NMPA for marketing in China for the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD).
